2023 RAISE Pilot Grant Awardees
- bridgetkeogh
- Sep 9
- 3 min read
Changes in contraception and sterilization use patterns among reproductive-age males and females in Pennsylvania following constrained abortion access.
PIs: Paula Chatterjee, MD, MPH; Alice Abernathy, MD, MSHP
Background: Access to effective contraception is essential to sex equity. The US Supreme Court decision Dobbs v. Jackson Women’s Health (Dobbs) reshaped access to abortion and may have produced changes in contraception and sterilization uptake.
Objective: Evaluate changes in contraception use and sterilization procedures for males and females, before and after the Dobbs decision in Pennsylvania, where abortion policy is subject to intense debate, and demographic characteristics permit comparisons of subpopulations of interest.
Hypothesis: Following the Dobbs decision, females shifted contraception use to favor more efficacious methods, and sterilization procedures rose among both males and females, narrowing extant gender gaps in sterilization.
Methods: The exposures include the Dobbs decision 1) leak and 2) final decision. The primary outcomes of interest, contraception use and sterilization, will be identified from claims data from the Pennsylvania Health Care Cost Containment Council. Descriptive statistics will be used to characterize patients seeking contraception and sterilization procedures (age, race, ethnicity, insurance, income, educational attainment, urban vs rural residence, zip code, proximity to abortion clinic). We will plot the unadjusted utilization rates of contraception and sterilization per population per year, before and after the exposures, stratified by sex. We will use an interrupted time series to establish the underlying trend in Pennsylvania which was “interrupted” by Dobbs which will allow us to deduce the impact of Dobbs on contraception use and sterilization procedures among males and females in Pennsylvania.
Brain growth charts for delineating sex and pubertal effects in human neuroanatomy
PIs: Aaron Alexander-Bloch, MD, PhD; Margaret Gardner, PhD; Sheila Shanmugan, MD, PhD;Russell T. Shinohara, PhD
Sex differences in neuroanatomy must be thoroughly understood if we are to identify and treat the effects of disease or aging in either female or male brains. Yet, sex biases in brain structure remain hotly debated. Previous neuroimaging studies identified widespread sex differences in brain morphology above and beyond sex-differences in total brain size or height, but replicability has been hampered by underpowered samples and lack of rigor in statistical modeling. Sex effects on neuroanatomy are further complicated by puberty, a multiscale developmental process that is strongly correlated with—yet systematically independent from— chronological age. Sex and puberty have interactive, nonlinear, and age-varying effects on brain structure. However, we lack a comprehensive, well-powered quantification of these effects. Here, we will generate sex-informed growth charts of brain development and aging, using a recently validated statistical modeling approach based on consortium-level data comprising over 100,000 MRI scans from 0-100 years (Aim 1). Using validated measures of pubertal stage coupled with over 15,000 MRI scans in participants under age 25, we will then investigate specific contributions of puberty to structural brain development (Aim 2). We propose to demonstrate that accurate, sex-informed brain growth charts improve sensitivity to disease effects in neuropsychiatric disorders, which often have sex differences in symptomatology, prevalence, and age of onset. The results of this project will enable our team to pursue NIH funding for translational studies that deploy sex-specific brain growth charts to analyze clinically-acquired MRIs in a treatment setting and to develop personalized imaging-genetic markers for neuropsychiatric disorders.
Sex Hormones and Inflammatory Biomarkers in Females with Sickle Cell Disease
PIs: Andrea Roe, MD, MPH; Kandace Gollomp, MD
Sickle cell disease (SCD) is characterized by debilitating pain episodes, known as vaso-occlusive crisis (VOC), and there is a significant sex disparity in VOC in SCD: females experience more frequent and more severe VOC than males. Females with SCD also often experience VOC pain, distinct from dysmenorrhea, during the week prior to and during menses. This sex disparity and cyclic pattern raise the possibility of a sex-specific pathophysiology to VOC in SCD. Markers of inflammation are elevated during VOC compared to baseline in SCD, and they also vary across the menstrual cycle in healthy females. We recently analyzed samples from the Penn Medicine BioBank (PMBB) to measure CRP and markers of inflammation and discovered that females with SCD had significantly higher C-reactive protein levels during the follicular phase of the menstrual cycle compared with the luteal phase, which could be linked to the cyclic pattern of VOC. We will use separate funding to recruit 40 patients with SCD during hospitalization for VOC, with repeat assessment after VOC resolution. With the proposed RAISE funding, we seek to characterize classic and novel biomarkers of inflammation, as well as cellular adhesion and clot formation, in what will be the largest cohort of SCD patients assessed at baseline and during VOC. We will stratify this cohort by sex to prospectively validate our preliminary data from the PMBB samples, explore associations with these novel measures, and potentially support our hypothesis that cyclic variation in inflammation across the menstrual cycle predisposes females with SCD to VOC.